633 related articles for article (PubMed ID: 18977540)
21. Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules.
Wilkerson MJ; Dolce K; Koopman T; Shuman W; Chun R; Garrett L; Barber L; Avery A
Vet Immunol Immunopathol; 2005 Jul; 106(3-4):179-96. PubMed ID: 15963817
[TBL] [Abstract][Full Text] [Related]
22. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
[TBL] [Abstract][Full Text] [Related]
23. Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction.
Pennell N; Woods A; Reis M; Buckstein R; Spaner D; Imrie K; Hewitt K; Boudreau A; Seth A; Berinstein NL
J Mol Diagn; 2006 Feb; 8(1):40-50. PubMed ID: 16436633
[TBL] [Abstract][Full Text] [Related]
24. Study of minimal residual disease in B-cell lineage acute lymphoblastic leukemia of childhood, using clone-specific probes.
Botsonis T; Tsangaris GT; Mikraki V; Tzortzatou-Stathopoulou F
Anticancer Res; 1999; 19(3B):2211-20. PubMed ID: 10472333
[TBL] [Abstract][Full Text] [Related]
25. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
26. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P
Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280
[TBL] [Abstract][Full Text] [Related]
27. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A
Ann Hematol; 2002 May; 81(5):258-66. PubMed ID: 12029535
[TBL] [Abstract][Full Text] [Related]
28. [Establishment of a real time quantitative-PCR assay for detection of TCR VgammaI-Jgamma gene rearrangement in acute lymphoblastic leukemia patients].
Jiang XG; Xu B; Xu WJ; Li B
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):425-8. PubMed ID: 15355697
[TBL] [Abstract][Full Text] [Related]
29. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
[TBL] [Abstract][Full Text] [Related]
30. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
Chen JS; Hsiao CC; Sheen JM; Cheng CN
Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
[TBL] [Abstract][Full Text] [Related]
31. Detection of minimal residual disease in peripheral blood prior to clinical relapse of childhood acute lymphoblastic leukaemia using PCR.
Lal A; Kwan E; Haber M; Norris MD; Marshall GM
Mol Cell Probes; 2001 Apr; 15(2):99-103. PubMed ID: 11292328
[TBL] [Abstract][Full Text] [Related]
32. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
[TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
34. [The minimal residual disease (MRD) in hematological malignancies].
Yokota S; Okamoto T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):762-8. PubMed ID: 11432342
[TBL] [Abstract][Full Text] [Related]
35. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Kasai M; Kakinoki Y; Masauzi N; Morioka M; Kawamura T; Iwasaki H; Asaka M; Imamura M
Am J Hematol; 2005 Nov; 80(3):181-7. PubMed ID: 16247752
[TBL] [Abstract][Full Text] [Related]
36. [Detection of residual disease in follicular lymphomas using the PCR technique: importance of clono-specific probes].
al Saati T; Galoin S; Roda D; Huynh A; Attal M; Delsol G
Bull Cancer; 1998 Oct; 85(10):847-54. PubMed ID: 9835862
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
Ryan J; Quinn F; Meunier A; Boublikova L; Crampe M; Tewari P; O'Marcaigh A; Stallings R; Neat M; O'Meara A; Breatnach F; McCann S; Browne P; Smith O; Lawler M
Br J Haematol; 2009 Jan; 144(1):107-15. PubMed ID: 19016726
[TBL] [Abstract][Full Text] [Related]
38. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy.
Martin S; Fischer C; Free M; Kurreck B; Stockinger H; Fenk R; Arnold C; Kliszewski S; Meckenstock G; Haas R; Kronenwett R
Eur J Haematol; 2005 Apr; 74(4):282-92. PubMed ID: 15777339
[TBL] [Abstract][Full Text] [Related]
39. Detection of minimal residual disease in B-lymphoproliferative disorders: a three step SSCP-PCR method.
Miglino M; Grasso R; Pietrasanta D; Palmisano GL; Berisso G; Clavio M; Pierri I; Santini G; Canepa L; Gobbi M
J Exp Clin Cancer Res; 2001 Mar; 20(1):95-101. PubMed ID: 11370837
[TBL] [Abstract][Full Text] [Related]
40. Detection and monitoring of minimal residual disease by quantitative real-time PCR.
Schüler F; Dölken G
Clin Chim Acta; 2006 Jan; 363(1-2):147-56. PubMed ID: 16154122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]